

Interview Summary	Application No. 08/266,154	Applicant(s) Morrison et al
	Examiner Julie E. Reeves, Ph.D.	Group Art Unit 1806

All participants (applicant, applicant's representative, PTO personnel):

(1) Julie E. Reeves, Ph.D.

(3) _____

(2) Vicki Veenker

(4) _____

Date of Interview Oct 22, 1997

Type: Telephonic Personal (copy is given to applicant applicant's representative).

Exhibit shown or demonstration conducted: Yes No. If yes, brief description:

Agreement was reached. was not reached.

Claim(s) discussed: all pending

Identification of prior art discussed:

none

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:

Applicants prefer the scope of the term "lymphoid" in place of "lymphocyte" as they felt that the plasma cell J558L and P3 used in the examples would not be encompassed by the term "lymphocyte". Examiner pointed out that the specification does not provide support for lymphoid cells and that the art recognized definition of lymphoid is rather vague. Examiner suggested that the specification may provide support for the lymphocyte lineage which may encompass plasma cells or that the references used to describe J558L and P3 may mention that the myeloma is a tumor cell of a plasma cell because these cells make portions of immunoglobulins prior to transfection. The final paragraph of the specification provides support for incorporation by reference. Applicants will try to submit renumbered and amended claims by November 5th.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign and stamp this form unless it is an attachment to a signed Office action.

Draft

96 78 A method for producing a functional immunoglobulin comprising a heavy chain and a light chain, which comprises the steps of:

(a) transfecting a transformed mammalian lymphocytic cell with a first

DNA molecule coding for a first chain of the immunoglobulin;

(b) transfecting the cell with a second DNA molecule, said second

DNA molecule coding for a second chain of the immunoglobulin, said second

chain being a chain other than the first chain and said first and second chains being

either the heavy chain or the light chain; and

(c) maintaining the cell in a nutrient medium, so that the cell expresses

the first and second DNA molecules and the resultant chains are intracellularly

assembled together to form the immunoglobulin which is then secreted in a form

capable of specifically binding to antigen

wherein prior to step (a) the cell does not express a functional immunoglobulin capable of specifically binding antigen.

97 79 A method as recited in claim 78 wherein the cell is transfected via protoplast fusion.

98 80 A method as recited in claim 78 wherein the cell is transfected via calcium phosphate precipitation.

99 43 A method as recited in claim 78 wherein the cell is a myeloma cell.

100 44 A method as recited in claim 43 wherein the cell is a murine myeloma cell.

101 81 A method as recited in claim 78 wherein the cell does not endogenously produce any immunoglobulin chains.

Draft

162

46.

A method as recited in claim 81 wherein the cell is a murine P₃ cell.

161

96

163

82.

A method as recited in claim 78 wherein prior to step (a) the cell endogenously produces an immunoglobulin light chain or an immunoglobulin heavy chain, but not both.

164

48.

A method as recited in claim 82 wherein the cell is a murine J558L cell.

165

83.

A method as recited in claim 78 wherein the immunoglobulin comprises the variable region found in a first mammalian species and comprises the constant region found in a second mammalian species, said second mammalian species being other than the first mammalian species.

166

84.

A method for producing a functional immunoglobulin comprising a heavy chain and a light chain, which comprises the steps of:

(a)

transfected a transformed mammalian lymphocytic cell with a plasmid comprising a first DNA molecule coding for a first chain of the immunoglobulin and a second DNA molecule coding for a second chain of the immunoglobulin, said second chain being a chain other than the first chain and said first and second chains being either the heavy chain or the light chain; and

(b)

maintaining the cell in a nutrient medium so that the cell expresses said first DNA molecule and said second DNA molecule and the resultant chains are intracellularly assembled together to form the immunoglobulin which is then secreted in a form capable of specifically binding to antigen

wherein prior to step (a) the cell does not express a functional immunoglobulin capable of specifically binding antigen.

Draft

- 107 85. A method as recited in claim ~~84~~ wherein the cell is transfected via
protoplast fusion. 106
- 108 86. A method as recited in claim ~~84~~ wherein the cell is transfected via
calcium phosphate precipitation. 106
- 109 87. A method as recited in claim ~~84~~ wherein the cell is a myeloma cell. 106
- 110 88. A method as recited in claim ~~84~~ wherein the cell is a murine
myeloma cell. 106
- 111 87. A method as recited in claim ~~84~~ wherein the cell does not
endogenously produce any immunoglobulin chains. 111
- 112 88. A method as recited in claim ~~87~~ wherein the cell is a murine P₃ cell. 106
- 113 88. A method as recited in claim ~~84~~ wherein prior to step (a) the cell
endogenously produces an immunoglobulin light chain or an immunoglobulin heavy chain,
which endogenously-produced heavy chain is not secreted in a form capable of specifically
binding to antigen, but not both. 113
- 114 88. A method as recited in claim ~~88~~ wherein the cell is a murine J558L
cell. 113
- 115 89. A method as recited in claim ~~84~~ wherein the immunoglobulin
comprises the variable region found in a first mammalian species and comprises the
constant region found in a second mammalian species, said second mammalian species
being other than the first mammalian species. 106
- 116 90. A method for producing a functional immunoglobulin comprising a
heavy chain and a light chain which comprises the steps of:

Draft

(a) maintaining in a nutrient medium a transformed mammalian lymphocytic cell, said cell having been transfected with a first DNA molecule coding for a first chain of the immunoglobulin and a second DNA molecule coding for a second chain of the immunoglobulin, said second chain being a chain other than the first chain and said first and second chains being either the heavy chain or the light chain;

(b) expressing from said cell the heavy chain and the light chain functionally assembled together to form said immunoglobulin which is then secreted in a form capable of binding antigen; and

(c) recovering said immunoglobulin wherein prior to being transfected, the cell does not express a functional immunoglobulin capable of specifically binding antigen.

117 91. A method as recited in claim 90 wherein the cell is transfected via protoplast fusion. 116

118 92. A method as recited in claim 90 wherein the cell is transfected via calcium phosphate precipitation. 116

119 91. A method as recited in claim 90 wherein the cell is a myeloma cell. 116

120 92. A method as recited in claim 71 wherein the cell is a murine myeloma cell. 119

121 93. A method as recited in claim 90 wherein the cell does not endogenously produce any immunoglobulin chains. 116

122 94. A method as recited in claim 93 wherein the cell is a murine P₃ cell. 121

123 94. A method as recited in claim 90 wherein prior to being transfected the cell endogenously produces an immunoglobulin light chain or an immunoglobulin heavy chain, but not both. 116

Draft

124 76. A method as recited in claim 94 wherein the cell is a murine J558L
cell.

125 76. A method as recited in claim 90 wherein the immunoglobulin
comprises the variable region found in a first mammalian source and comprises the
constant region found in a second mammalian species, said second mammalian species
being other than the first mammalian species.

126 76. A method as recited in claim 90 wherein the immunoglobulin
comprises the variable region found in a first mammalian source and comprises the
constant region found in a second mammalian species, said second mammalian species
being other than the first mammalian species.